Engineered immune cells take on tough blood cancers in early trial
NCT ID NCT03853616
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called MB-CART19.1 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to find a safe dose and see if it's feasible to give this treatment to about 48 adults and children.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MB-CART19.1 (a type of CAR T cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat B cell cancers that have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 48 participants, so safety and dosing are still being figured out. CAR T cell therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - University clinic, pediatric clinic with focus on oncology and hematology
Berlin, 13353, Germany
-
Children's Hospital of Dr. von Hauner by Ludwig-Maximilian University
Munich, 80337, Germany
-
Tuebingen University clinic, medical university clinic for internal medicine
Tübingen, 72076, Germany
-
University clinic for children and youth medicine
Tübingen, 72076, Germany
-
University clinic, pediatric hematology and oncology
Würzburg, 97070, Germany
-
University medicine Goettingen, Clinic of hematology and medical oncology
Göttingen, 37075, Germany
-
Universitätsklinikum Erlangen
Erlangen, 91054, Germany
-
Universitätsklinikum Münster - Klink für Kinderheilkunde und Jugendmedizin / Pädiatrische Hämatologie und Onkologie
Münster, 48149, Germany
-
Universitätsklinikum Münster - Medizinische Klinik A / KMT Zentrum
Münster, 48149, Germany